Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02721069
Recruitment Status : Completed
First Posted : March 28, 2016
Results First Posted : January 31, 2022
Last Update Posted : January 31, 2022
Information provided by (Responsible Party):
Neurelis, Inc.

Brief Summary:
This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1

Condition or disease Intervention/treatment Phase
Acute Repetitive Seizures Breakthrough Seizures Drug: NRL-1 Phase 3

Detailed Description:
This is a Phase 3, repeat dose, open-label, safety study in Epilepsy subjects who have frequent breakthrough seizures or Acute Repetitive Seizures (ARS). NRL-1 will be administered as needed to treat bouts of those seizures over a 12-month period of time. Doses will be defined as 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight. A diary will be used to record the seizure and NRL-1 administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 175 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)
Actual Study Start Date : April 11, 2016
Actual Primary Completion Date : June 17, 2020
Actual Study Completion Date : July 23, 2020

Arm Intervention/treatment
Experimental: NRL-1
Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
Drug: NRL-1
Other Name: Intranasal diazepam

Primary Outcome Measures :
  1. Number of Participants Who Received NRL-1 (Valtoco) [ Time Frame: 12 months ]
    Assess the number of participants who received at least one dose of NRL-1 (Valtoco) during the study and comprised the safety population.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female subjects between the ages of 6 and 65 years, inclusive.
  2. Written informed consent to participate in the study.
  3. Subject has a clinical diagnosis of Epilepsy and while on a stable regimen of anti-epileptic medication, still experiences bouts of seizures (e.g. frequent break through seizures or Acute Repetitive Seizures [ARS]), and who, in the opinion of the Investigator, may need benzodiazepine intervention for seizure control at least 1 time a month on average.
  4. Subject has a qualified caregiver or medical professional available that can administer study medication in the event of a seizure.
  5. Subjects having either partial or generalized Epilepsy with motor seizures or seizures with clear alteration of awareness.
  6. Female subjects of childbearing potential, defined as having a menstrual cycle and who are not surgically sterile or less than two (2) years postmenopausal, must complete a pregnancy screen and agree to utilize one of the following forms of contraception during the trial and for 21 days after the last dose of study drug: abstinence, hormonal (oral, transdermal, implant, or injection), barrier (condom, diaphragm with spermicide), intrauterine device (IUD), or vasectomized partner (six months minimum). Subjects must have used the same method for at least one (1) month prior to starting the study.
  7. No clinically significant abnormal findings in the medical history, on the physical examination or electrocardiogram (QTcF<450 msec for males and QTcF<470 msec for females).
  8. Subjects and caregivers must agree to return to the study site for all study visits and must be willing to comply with all required study procedures.

Exclusion Criteria:

  1. A history of clinically significant gastrointestinal, renal, hepatic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject.
  2. Subject has had significant traumatic injury, major surgery or open biopsy within 30 days prior to study screening.
  3. Subjects with active major depression or a past suicide attempt, or any Suicidal Ideation of 3, 4, or 5 or any Suicidal Behavior in Lifetime using Columbia-Suicide Severity Rating Scale (C-SSRS). The pediatric C-SSRS should be used for subjects age 6 to 11. The adult C SSRS should be used for subjects 12 and greater years of age.
  4. A history of allergic or adverse responses to diazepam or any comparable or similar product.
  5. Participation in a clinical trial other than protocol DIAZ.001.04 within 30 days prior to Day 0. Participation in an observational (non-interventional) study is not excluded as long as there are no scheduling conflicts with this study.
  6. Positive serum pregnancy test (ß-hCG) at screening for subjects age 12 or greater.
  7. Positive blood screen for Human immunodeficiency virus (HIV), Hepatitis B surface antigen (HbSAg), or Hepatitis C, or a positive urine screen for alcohol or drugs of abuse, except marijuana use for medical reasons. When marijuana was used for medical reasons in the opinion of the investigator, it is not considered as drug abuse and the patient can be enrolled even if the marijuana metabolites in the urine revealed as positive.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02721069

Layout table for location information
United States, Arkansas
Clinical Trials, Inc.
Little Rock, Arkansas, United States, 72205
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New York
New York University Comprehensive Epilepsy Center
New York, New York, United States, 10016
United States, Pennsylvania
Thomas Jefferson University Hospital Laboratory
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Neurelis, Inc.
  Study Documents (Full-Text)

Documents provided by Neurelis, Inc.:
Study Protocol  [PDF] September 28, 2017
Statistical Analysis Plan  [PDF] July 8, 2020

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Neurelis, Inc. Identifier: NCT02721069    
Other Study ID Numbers: DIAZ.001.05
First Posted: March 28, 2016    Key Record Dates
Results First Posted: January 31, 2022
Last Update Posted: January 31, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Neurelis, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Adjuvants, Anesthesia
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Muscle Relaxants, Central
Neuromuscular Agents
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
Anesthetics, Intravenous
Anesthetics, General
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action